Skip to main content

Corporate News tagged:

Clinical capabilities

REPROCELL Corporate News

[PRESS RELEASE:] REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

08 February 2024

REPROCELL currently has two clinical pipelines under research and development: (1.) the stem cell product Stemchymal for spinocerebellar ataxia; (2.) iPSC-derived neuroglial cells for ALS (Amyotrophic Lateral Sclerosis). REPROCELL will soon...

Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu

31 January 2024

REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant, that is located in Larrabetzu, Spain. Histocell's manufacturing plant produces cell ther...

Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives

15 January 2024

SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cel...

End of 2023 Newsletter

15 December 2023

The end of the year might be approaching, but we’re not winding down at REPROCELL. The final half of 2023 has brought new services, collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This inclu...

REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs

04 October 2023

Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing. YOKOHAMA, Japan — REPROCELL Inc. today announced that it has entered into an agreement to grant Gameto Inc., a female-led biotechno...

Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer

28 June 2023

We are pleased to announce that REPROCELL has entered into a joint research agreement with Keio University regarding “transfer of technology for the production of Tumor Infiltrating Lymphocytes (TIL) for Advanced Medicine B - a phase II cli...

[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia

25 May 2023

Yokohama Japan, 25 May 2023: We are pleased to announce the results of the Phase II clinical trial in Japan (protocol number: RS-01) of our regenerative medicine product Stemchymal® (allogeneic adipose-derived mesenchymal stem cells) for th...

REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products

23 May 2023

Yokohama Japan, 23 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with Histocell. REPROCELL’s subcontracting pa...

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

03 May 2023

REPROCELL USA, a CRO, has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)”. The...

REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers

13 October 2022

Yokohama, Japan, 13 October 2022: REPROCELL Inc. and JTB Corp. will begin marketing "Personal iPS" (REPROCELL's iPSC storage and production service) overseas through the Japan Medical & Health Tourism Center (JMHC): a medical coordination d...

REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs

05 October 2022

Yokohama Japan, 5 October 2022: REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to make accessible REPROCELL’s unique induced Pluripotent Stem Cells (iPSCs) tec...

REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs

04 October 2022

YOKOHAMA, Japan: REPROCELL Inc. and San Antonio, Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. The agreement will expand REPROCELL’s global biomanufacturing ser...

Bioserve India granted NABL accreditation in the field of Genomics Testing

09 August 2022

Hyderabad, India - 9 August 2022: We are pleased to announce that Bioserve Biotechnologies India Pvt Ltd, a subsidiary of REPROCELL Inc, has received NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation...

Completion of Clinical Phase II Trials of Stemchymal in Japan

16 May 2022

Yokohama Japan, 16 May 2022: We are pleased to announce that the Clinical Phase II Trial of Stemchymal, a regenerative medicine product derived from somatic stem cells, has been completed in Japan. Previously, on 24 May 2021, we announced t...

REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service

02 September 2021

Yokohama Japan, 02 September 2021: REPROCELL have signed a Strategic Collaboration Agreement with TEXCELL JAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a c...

REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing

18 August 2021

Yokohama Japan, 18 August 2021: REPROCELL have signed a Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a contract manufa...

REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite

29 June 2021

Maryland, USA: REPROCELL has opened a new Seed iPSC Manufacture Suite (SiMS) in response to increasing demand for iPSC-derived Master Cell Banks (MCBs). At this new US facility, REPROCELL will provide a comprehensive workflow of clinical st...

REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant

21 June 2021

Yokohama, Japan: We are pleased to announce that REPROCELL will launch a new testing service of identification for Covid-19 variants, including the Indian (Delta), UK, South African, and Brazilian variants. These have all been identified as...

Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan

24 May 2021

We are pleased to announce that administrations of Stemchymal, a regenerative medicine product derived from somatic stem cells, have been completed to all enrolled patients in phase II clinical trial for the treatment of spinocerebellar ata...

VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL

18 May 2021

Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical researc...